Adacyte Therapeutics is a multinational company committed to the development of unique health technologies aimed at improving patients' health and its quality of life. Adacyte was established in 2018 with the commitment and responsibility to commercialize internationally a selective apheresis system with proven clinical efficacy for the treatment of certain autoimmune pathologies. Our patients inspire and guide us. What is important for them is also important for us. Their safety is our obsession and for that reason we develop medical devices that enable to address serious health problems. We are an honest, flexible, reliable, daring and fun team.